drug-dose adjustment in patients with hepatic diseases
TRANSCRIPT
![Page 1: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/1.jpg)
DRUG DOSE ADAPTATION IN PATEINTS WITH
HEPATIC DISEASESDr. AMREEN SABA ATTARIYA
POST GRADUATE STUDENT, DEPT OF PHARMACOLOGYM.R. MEDICAL COLLEGE, GULBARGA
INDIA
105/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 2: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/2.jpg)
OUTLINE OF TALK
INTRODUCTIONEPIDEMIOLOGYHEPATIC PATHOPHYSIOLOGYFEATURES OF LIVER DISEASEALTERED PK & PDGENERAL GUIDELINESRECOMMENDATIONSSPECIAL AGE GROUP CONSIDERATIONSSUMMARYREFERENCES 2
05/02/23
Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 3: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/3.jpg)
INTRODUCTION
• Liver plays a central role in PK of drugs• Site for drug biotransformation• Liver blood flow, binding to plasma protein &
biliary excretion influences PKdepend on normal functioning of liver
• Hepatic dysfunction increased sensitivity to both desired & AEDosage adjustment
305/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 4: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/4.jpg)
EPIDEMIOLOGY OF LIVER DISEASES
INDIA : LIVER DISEASE*
LIVER diseases rank no.10 in top 20 causes of death in India
4*WHO Publish Date: May 2014
Deaths % Rate World Rank
216,865 2.44 21.96 61
05/02/23
Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 5: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/5.jpg)
LEADING CAUSES FOR CHRONIC LIVER DISEASE*
• In west- alcohol & HCV• In India- alcohol & HBV
5
*Ray G:Trends of Chronic Liver Disease in a Tertiary Care Referral Hospital in Eastern India--www.ijph.in on Monday, February 08, 2016, IP:125.17.185.146]
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 6: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/6.jpg)
RISK OF LIVER DAMAGE BY DRUGS IS THOUGHT TO BE INCREASED BY
• Age 18 years or over• Obesity• Pregnancy• Consumption of alcohol• A genetic make-up that makes people more
susceptible to a drug's effects
605/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 7: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/7.jpg)
• In the US, approximately 2000 cases of acute liver failure occur annually
• Drugs account for over 50% of them (39% are due to acetaminophen, 13% are idiosyncratic ).
• Drugs account for 2-5% of cases of patients hospitalized with jaundice and approximately 10% of all cases of acute hepatitis.
705/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 8: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/8.jpg)
HEPATIC PATHOPHYSIOLOGY
• Numerous pathophysiologic changes in the liver that may influence PK*
• Results in 1.reduction in liver blood flow2.presence of intra- and extrahepatic portal-systemic
shunting3.reduction in number & activity of hepatocytes
8*Le Couteur DG et al 200505/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 9: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/9.jpg)
905/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 10: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/10.jpg)
1005/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 11: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/11.jpg)
MANIFESTATIONSEsophageal varicesEdema, ascitesImpaired liver parenchymal functionHepatic encephalopathy
1105/02/23
Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 12: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/12.jpg)
EFFECT ON OTHER ORGANSIntestine
LungsKidneys
1205/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 13: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/13.jpg)
DIAGNOSIS OF LIVER DISEASE
• Unfortunately-No simple endogenous marker available
• Child Pugh Score
1305/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 14: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/14.jpg)
FEATURES OF LIVER DISEASE*
• hepatic clearance of drugs• plasma protein production• First Pass Metabolism Bioavailability• drug metabolising enzymes activity• Impaired renal function• Higher sensitivity of central AE of opioids & renal
AE of NSAIDs
14
*Veerbeck RK, Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction review article: Eur J Clin Pharmacol (2008)05/02/23 Dr.A.S.Attariya:DoseAdjustmen
tInHepaticDis
![Page 15: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/15.jpg)
15
HEPATIC CLEARANCE*
Cli is the intrinsic hepatic clearance and fu the fraction of
a drug not bound to serum proteins (free fraction).
05/02/23
*Wilkinson, G.R., and Shand, D.G. 1975 A physiological approach to hepatic drug clearance, Clin. Pharmacol. Ther., 18, 377-90Dr.A.S.Attariya:DoseAdjustmen
tInHepaticDis
![Page 16: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/16.jpg)
16
“FLOW-LIMITED”
When (fu x Cli) >> Q, equation
can be simplified to Clhep ≈ Q
In this case, hepatic clearance is said to be blood flow-
limited and the drugs are called flow-limited or “high
extraction” drugs(HED)
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 17: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/17.jpg)
17
“ENZYME-LIMITED”
When (fu x Cli) is << Q , equation
can be simplified to Clhep ≈ (fu x Cli)
In this case, hepatic clearance is said to be “enzyme-limited” and the drugs are called enzyme-limited or “low extraction drugs(LED)”
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 18: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/18.jpg)
“ FLOW AND ENZYME LIMITED"
When (fu x Cli) ≈ Q The hepatic clearance of these
drugs is determined by both Q and (fu x Cli).
Drugs are therefore called Intermediate extraction
Drugs (IED)and cannot be assigned to either group.
05/02/23 18Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 19: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/19.jpg)
DIFFERENT CLASS OF DRUGS
• HED [E= >0.7]
• LED[E= <0.3]
• IED[E= 0.3-0.7]
1905/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 20: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/20.jpg)
2005/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 21: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/21.jpg)
21
HED OR FLOW LIMITED DRUGS
Clhep ≈ QAll disease that reduce Blood flow across the liver may
impair hepatic clearance of HED.
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 22: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/22.jpg)
DISEASES THAT INCREASE BA OF HED
1. CIRRHOSIS and/or PORTAL HYPERTENSION
are likely to have intra- and extra hepatic porto
systemic shunt
2. Diseases that impair blood flow to the liver (heart
failure, shock, major surgery, drugs like
EPINEPHRINE, B-BLOCKERS)2205/02/23 Dr.A.S.Attariya:DoseAdjustmen
tInHepaticDis
![Page 23: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/23.jpg)
23
ADJUSTMENT FOR HED
Hence for HED administered orally, both the initial
and the maintenance doses have to be reduced.
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 24: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/24.jpg)
DOSE ADJUSTMENT OF HED GIVEN IV
a normal initial dose can be administered and the
maintenance doses has to be reduce according to
hepatic blood flow.
2405/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 25: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/25.jpg)
2505/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 26: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/26.jpg)
2605/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 27: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/27.jpg)
2705/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 28: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/28.jpg)
2805/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 29: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/29.jpg)
LED : DOSE ADJUSTMENT
• For these drugs hepatic clearance is mainly determined by the activity of drug metabolizing enzymes (Cli).
• Clhep ≈ (fu x Cli)
• In liver disease The maintenance dose of these
drugs should be reduced, whereas therapy can be
started with a normal dose.
• But how to adjust the maintenance dose ?3005/02/23 Dr.A.S.Attariya:DoseAdjustmen
tInHepaticDis
![Page 30: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/30.jpg)
LOW EXTRACTION DRUGS :ADJUSTMENT OF MAINTENANCE DOSE
• The reduction in Cli associated with liver disease appears to be function of the Child’s score, an useful classification scheme that is used to formulate drug dosing recommendations for patients with liver disease
3105/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 31: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/31.jpg)
32
Pugh Modification Of Child’s Classification Of Liver
Disease Severity
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 32: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/32.jpg)
3305/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 33: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/33.jpg)
34
LOW EXTRACTION DRUGS: ADJUSTMENT OF MAINTENANCE DOSE
Patients with Child class A a maintenance dose of 50% of nor.
patients with Child class B
a maintenance dose of 25% of nor.
Patients with Child class C use of drugs whose safety hasbeen demonstrated in clinical trials and/or whose kinetics is not affected by liver disease or for which therapeutic drug monitoring is available05/02/23 Dr.A.S.Attariya:DoseAdjustmen
tInHepaticDis
![Page 34: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/34.jpg)
LED with high binding to Albumin ≥ 90%
• It represent an exception to the rule that say for
LED,hepatic clearance is mainly determined by the
activity of drug metabolizing enzymes (Cli)• Clhep ≈ (fu x Cli)
• Liver disease can reduce Sr.Alb concentration
• Therefore increase the unbound fraction of the drug fu
3505/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 35: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/35.jpg)
36
LED WITH A HIGH BINDING TO ALBUMIN (≥90%)
In order to avoid toxicity by overdosing, free drug levels
should be determined and used to guide therapy of such
drugs in livers disease.
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 36: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/36.jpg)
3705/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 37: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/37.jpg)
3805/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 38: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/38.jpg)
3905/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 39: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/39.jpg)
4005/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 40: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/40.jpg)
05/02/23 41Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 41: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/41.jpg)
4205/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 42: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/42.jpg)
4305/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 43: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/43.jpg)
4405/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 44: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/44.jpg)
4505/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 45: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/45.jpg)
IED: DOSE ADJUSTMENT
• Since BA slowly rises in case of blood flow reduction, therapy has to be started with INITIAL LOW DOSE
• But for MAINTENANCE DOSE it has to be calculated as that for LED
4605/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 46: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/46.jpg)
4705/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 47: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/47.jpg)
4805/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 48: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/48.jpg)
ALTERED ABSORPTION
• BA of the sedative/hypnotic agent CLORMETHIAZOLE is increased more than 10fold in cirrhosis*
• CARVEDILOL therapy should be started in cirrhotic patients at about 1/5th of the normal dosage**
49
*Pentikäinen PJ et al Eur J Clin Pharmacol**Neugebauer G, et al: PK & BA of carvedilol in patients with liver cirrhosis
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 49: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/49.jpg)
50
EFFECT ON PPB
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 50: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/50.jpg)
EFFECT ON PPB & DISTRIBUTION contd…
• Decreased PPB of certain drugs • aVd of β-lactam antibacterial CEFODIZIME was
shown to be 3 times larger in cirrhosis*(thus needs larger loading dose)
51
*Touny M et al PK of cefodizime in patients with liver cirrhosis and ascites.
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 51: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/51.jpg)
ALTERED METABOLISM
• CYP450 enzyme activity is differentially affected in liver disease*.
• Several PK studies have shown a decrease in the clearance of drugs metabolized by CYP3A4/3A5 such as MIDAZOLAM,NIFEDIPINE , EVEROLIMUS
• Glucuronidation reactions are often considered to be affected to a lesser extent by liver cirrhosis than CYP450-mediated reactions**
52
*Frye RF et al(2006) :In Clin Pharmacol Ther**Elbekai RH et al(2000)05/02/23 Dr.A.S.Attariya:DoseAdjustmen
tInHepaticDis
![Page 52: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/52.jpg)
5305/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 53: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/53.jpg)
EFFECT ON RENAL EXCRETION
• Defn of hepatorenal syndrome• Reduced renal excretion of diuretics, H2
antagonists, levetiracetam in advanced cirrhosis*
54
* Gonzales G, Eur J Clin Pharmacol
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 54: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/54.jpg)
EFFECT ON PD
• The most important changes in PD with β-blockersdiureticsopioid analgesicsanxiolytics and sedatives.
5505/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 55: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/55.jpg)
GENERAL GUIDELINES
1.Clinical signs & symptoms for hepatotoxicity should be sought
2.Hepatotoxic drugs should be avoided if possible
Monitoring LFTs
1. Sr.Bilirubin levels >4-5mg/dl
2. PT >1.5 times control
3. Sr.Albumin <2.0g/dl
4. Elevated ALT & AST
5605/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 56: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/56.jpg)
RECOMMENDATION
FDA and the European Medicines Evaluation Agency (EMEA) aimed at generating, if possible, specific dosage recommendations for patients with hepatic dysfunction
NEED TO DEVELOP MORE SENSITIVE LIVER FUNCTION TESTS
5705/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 57: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/57.jpg)
DRUGS REPORTED (OR PREDICTED) TO HAVE AN INCREASED RISK OF HEPATOTOXICITY IN PATIENTS WITH LIVER DISEASE
• ATT (INH, pyrazinamide, rifampicin) • HAART (e.g. nevirapine) • Methimazole • Methotrexate • Nefazodone• Propoxyphene • Valproate • Vitamin A
5805/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 58: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/58.jpg)
DRUGS WITHDRAWN FROM THE MARKET SECONDARY TO HEPATOTOXICITY*
• Bromfenac(NSAID)• Troglitazone(OHA)• Kava Kava(antianxiety herb)• Pemoline(for ADHD & narcolepsy)• Felbamate(for partial seizures)• Tolcapone (Antiparkinson)• Trovafloxacin(antibiotic)• Tienilic Acid(diuretic)• Zileuton(asthma)
59
*Drug-Induced Hepatotoxicity, Nilesh Mehta in MEDSCAPE
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 59: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/59.jpg)
60
SPECIAL AGE GROUPS
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 60: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/60.jpg)
PEDIATRIC AGE GROUP
• Pharmacokinetics differs in neonates, especially prematures, because their organs are not fully developed.
• Until 1 year, liver function is still immature.• Children of 1 to 12 years have increased activity of
metabolizing enzymes
6105/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 61: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/61.jpg)
HEPATIC DISEASE IN NEONATES AND INFANTS*
• Poor intrinsic metabolic capacity of enzymes• Decreased albumin binding of drugs• Viral hepatitis will not affect blood flow to
liverno interference with clearance• Avoid PCT & other NSAIDs metabolised by liver,
instead use IBUPROFEN(excreted by kidney) in low dose
62
*Seth SD:Drugs in pregnancy & pediatrics
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 62: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/62.jpg)
DRUGS CONTRAINDICATED IN CHILDREN WITH LIVER DISEASES
• CHLORAMPHENICOLGrey baby syndrome• ASPIRIN Reye’s syndrome• PHOTOTHERAPY Bronze baby syndrome• PCT Pct induced hepatotoxicity
6305/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 63: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/63.jpg)
64
BRONZE BABY SYNDROME
GREY BABY SYNDROME
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 64: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/64.jpg)
PREGNANCY
CAUTIOUS USE OF drugs that cross placenta to avoid toxic effects(LA, narcotics used during labor)
6505/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 65: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/65.jpg)
GERIATRIC AGE GROUP
• In elderly, physiologic changes alters all pharmacokinetic processes in the liver.
• Many drugs are metabolized more slowly and accumulate with chronic administration.
6605/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 66: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/66.jpg)
AIM OF PK STUDIES IN ELDERLY
TO STUDY PARAMETERS :• Plasma t1/2
• Plasma drug clearance• Time to peak plasma concentration• Area under curve• aVd for individual drugs
6705/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 67: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/67.jpg)
DRUGS WHOSE HEPATIC METABOLISM IS REDUCED IN ELDERLY
68
OXIDATION, HYDROXYLATION
DEALKYLATION REDUCTIONNITROREDUCTION
AlprazolamBarbituratesCarbamazepineIbuprofenPhenytoinWarfarinPropranolol
DiazepamLidocaineTheophylline
Nitrazepam
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 68: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/68.jpg)
SUMMARY
• Cirrhosis results in numerous pathophysiological changes influences PK of drugs.
• Be cautious while prescribing drugs in liver diseases• Thorough knowledge of hepatic pathology for dose
adjustment• Benefits vs AE are to be weighed.• Need to develop sensitive LFT which serves as a
cornerstone for dosage adjustment• Advanced liver diseasedose modification for renally
cleared drugs is also needed.• Utmost care while prescribing in special age groups
6905/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 69: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/69.jpg)
70
HED
BromocriptinLdopaMorphieneVerapamilsumatriptan
IED
CiprofloxCarvedilolDiltiazemAtorva, Prava, SimvaOmeprazoleMidazolamcodiene
LED(low PPB)
AlprazolamDoxycyclineMetronidINHPCTMpredni
LED(high PPB)
DiazepamTolcaponeCeftriaxoneRifampicinPrednisolone
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 70: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/70.jpg)
DRUGS C/I IN LIVER DISEASE
71
Methotrexate Niacin Naltrexone MetforminTolcapone StatinsTacrine Valproic acidMethyldopaClonazepam
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 71: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/71.jpg)
POTENTIAL CHANGES IN DRUG HANDLING IN CIRRHOSIS
7205/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 72: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/72.jpg)
EFFECTS OF CIRRHOSIS ON THERAPEUTIC DRUGRESPONSE
7305/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 73: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/73.jpg)
74
STAY HEALTHY
05/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis
![Page 74: DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES](https://reader035.vdocuments.us/reader035/viewer/2022070517/58cf8f211a28ab65538b49b3/html5/thumbnails/74.jpg)
REFERENCES…
• Herrine SK: Effects of Liver Disorders on Drugs, MSD(Merck Manuals in the United States and Canada) manual of diagnosis & therapy
• Ray G:Trends of Chronic Liver Disease in a Tertiary Care Referral Hospital in Eastern India--www.ijph.in on Feb 08, 2016, IP: 125.17.185.146
• Wilkinson GR, Shand DG. 1975 A physiological approach to hepatic drug clearance, Clin. Pharmacol. Ther., 18, 377-90
• Nicholas HG, Holford: In Katzung Basic And Clinical Pharmacology, McGraw Hill Education 13th ed P.No 80-84
• Veerbeck RK, Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction review article: Eur J Clin Pharmacol (2008) 64:1147–1161 DOI 10.1007/s00228-008-0553-z
• Sharma HL, Sharma KL:In Principles of pharmacology 2nd ed P.No.38• Seth SD:Drugs in pregnancy & pediatrics, 2nd ed P.No.721• Jorge L. Herrera, University of South Alabama College of Medicine,
Mobile, AL – Published November 2007. Updated December 2012 7505/02/23 Dr.A.S.Attariya:DoseAdjustmentInHepaticDis